ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO935

A Single Center Study of SARS-CoV-2 Spike Antibody Response to Vaccination in Renal Transplant Recipients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Basuli, Debargha, East Carolina University, Greenville, North Carolina, United States
  • Ross, Bonnie, East Carolina University, Greenville, North Carolina, United States
  • Briley, Kimberly, East Carolina University, Greenville, North Carolina, United States
  • Ali, Hassam, East Carolina University, Greenville, North Carolina, United States
  • Rebellato, Lorita, East Carolina University, Greenville, North Carolina, United States
Background

Kidney transplant recipients are at high risk of mortality and complications related to COVID-19. Vaccination remains the most important strategy to prevent severe disease in this vulnerable population. The goal of this study was to evaluate the antibody response to mRNA vaccines in kidney transplant recipients.

Methods

We studied anti-spike IgG response to mRNA vaccines (BNT162b2 and mRNA-1273) against SARS-CoV-2 in adult kidney transplant recipients in a single center. Preserved blood samples of kidney transplant patients undergoing routine monitoring were used. The LABScreen COVID Plus Assay (One Lambda) was used to detect SARS-CoV-2 antibody response. Categorical variables were compared using the Fisher’s exact test, and continuous variables were compared using a t-test.

Results

Among 120 subjects receiving two doses of vaccines, only 74 (61.7%) elicited a positive response with anti-Spike antibody. After a third dose/first booster vaccine, 35 out of 43 (81.4%) kidney subjects had a positive response. There was no statistically significant difference between the responders and non-responders in terms of age, gender, race, blood group, time since transplant, vaccine type. A third dose vaccine produced statistically significant increase in antibody response compared to 2 doses only. A third dose induced a serological response in 7 out of 8 subjects (87.5%) who did not respond after 2 doses of vaccine. None of the patients developed donor specific HLA antibody in response to COVID-19 infection or the vaccine.

Conclusion

In this single center retrospective study, we demonstrated that the antibody response to SARS-CoV-2 mRNA vaccine was most prevalent after 4 months since the second dose. In addition, a third dose induced an antibody response in a larger number of kidney transplant recipients (81.3% vs 61.67%, p value 0.018), suggesting that this patient population may benefit from receiving multiple doses of mRNA vaccines.